Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Keytruda was the first immunotherapy called a checkpoint inhibitor that was approved for first‐line treatment of lung cancer. Below you’ll find common questions and answers about Keytruda to ...

However while melanoma is relatively rare, lung cancer is by far the UK’s biggest cancer killer. It causes 22% of all cancer deaths in men and women, more than breast and bowel cancer combined.

In addition, treating lung cancer patients with Keytruda improved quality of life. Among those who got the immunotherapy drug, only 18% experienced severe side effects, compared with 41% on ...

Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug ...

Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the immunotherapy as an add-on to other types of treatment for early-stage lung and skin cancer ...

Immunotherapy: A new weapon against cancer 06:58. Rates of serious side effects were similar, but twice as many in the Keytruda group dropped out because of them.

LOS ANGELES (KABC) -- Researchers call the drug Keytruda a new and exciting option in treating the leading cause of cancer deaths worldwide. One local lung cancer patient experienced what doctors ...

Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to ...

Keytruda, approved October last year for lung cancer and in 2014 for melanoma, is pricey — costing about $150,000 a year for a course of treatment. It’s approved for use with a specific test ...

Keytruda is now the second FDA-approved PD-1 inhibitor in lung cancer, and first across all NSCLC histologies. The PD-1 agent Opdivo (nivolumab) was approved in March 2015 for patients with NSCLC who ...